BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 20102884)

  • 1. Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial).
    McBane RD; Hardison RM; Sobel BE;
    Am J Cardiol; 2010 Jan; 105(1):17-24. PubMed ID: 20102884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
    Sobel BE; Hardison RM; Genuth S; Brooks MM; McBane RD; Schneider DJ; Pratley RE; Huber K; Wolk R; Krishnaswami A; Frye RL;
    Circulation; 2011 Aug; 124(6):695-703. PubMed ID: 21768545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type 2 Diabetes and Cardiovascular Factors Contrasted with Fibrinolysis Disorders in the Blood of Patients with Peripheral Arterial Disease.
    Wieczór R; Wieczór AM; Kulwas A; Rość D
    Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31336615
    [No Abstract]   [Full Text] [Related]  

  • 4. Thrombotic/Thrombolytic Balance as a Cardiac Treatment Determinant in Patients With Diabetes Mellitus and Coronary Artery Disease.
    Tsujimoto T; Kajio H
    J Am Heart Assoc; 2019 Jan; 8(2):e011207. PubMed ID: 30646801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1.
    Aso Y; Matsumoto S; Fujiwara Y; Tayama K; Inukai T; Takemura Y
    Metabolism; 2002 Apr; 51(4):471-6. PubMed ID: 11912556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
    Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
    Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evolution of fibrinolysis status with D-dimer level and the rate of plasminogen activator inhibitor type-1/D-dimer in acute coronary syndrome patients complicated with impaired glucose tolerance].
    Wu WD; Xu YH; Tan PY
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2003 Aug; 15(8):472-5. PubMed ID: 12919647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
    van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
    Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Levels of tissue-type plasminogen activator (T-PA), its inhibitor (PAI-1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus].
    Kvasnicka J; Skrha J; Perusicová J; Maslowská H; Pochopová L
    Cas Lek Cesk; 1996 Mar; 135(6):174-7. PubMed ID: 8681360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Hazard of Myocardial Infarction With Insulin-Provision Therapy in Actively Smoking Patients With Diabetes Mellitus and Stable Ischemic Heart Disease: The BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Trial.
    Khan AA; Chung MJ; Novak E; Brown DL
    J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28903941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical activity status and adverse age-related differences in coagulation and fibrinolytic factors in women.
    DeSouza CA; Jones PP; Seals DR
    Arterioscler Thromb Vasc Biol; 1998 Mar; 18(3):362-8. PubMed ID: 9514404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study.
    Belalcazar LM; Ballantyne CM; Lang W; Haffner SM; Rushing J; Schwenke DC; Pi-Sunyer FX; Tracy RP;
    Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1689-95. PubMed ID: 21512162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective double-arm study of fibrinolysis in surgical patients.
    Kosir MA; Schmittinger L; Barno-Winarski L; Duddella P; Pone M; Perales A; Lange P; Brish LK; McGee K; Beleski K; Pawlak J; Mammen E; Sajahan NP; Kozol RA
    J Surg Res; 1998 Jan; 74(1):96-101. PubMed ID: 9536981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting.
    Walter T; Szabo S; Kazmaier S; Suselbeck T; Borggrefe M; Hoffmeister HM
    Thorac Cardiovasc Surg; 2009 Sep; 57(6):368-71. PubMed ID: 19707983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects.
    Al-Hamodi Z; Ismail IS; Saif-Ali R; Ahmed KA; Muniandy S
    Cardiovasc Diabetol; 2011 Mar; 10():23. PubMed ID: 21414238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
    Konieczynska M; Fil K; Bazanek M; Undas A
    Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 are correlated with the presence of transplant coronary artery disease in cardiac transplant recipients.
    Warshofsky MK; Wasserman HS; Wang W; Teng P; Sciacca R; Apfelbaum M; Schwartz A; Michler RE; Mancini DM; Cannon PJ; Rabbani LE
    Am J Cardiol; 1997 Jul; 80(2):145-9. PubMed ID: 9230149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
    Lahlou-Laforet K; Alhenc-Gelas M; Pornin M; Bydlowski S; Seigneur E; Benetos A; Kierzin JM; Scarabin PY; Ducimetiere P; Aiach M; Guize L; Consoli SM
    Am J Cardiol; 2006 May; 97(9):1287-91. PubMed ID: 16635597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral artery disease in type 2 diabetes: the role of fibrinolysis.
    Lapolla A; Piarulli F; Sartore G; Rossetti C; Martano L; Carraro P; De Paoli M; Fedele D
    Thromb Haemost; 2003 Jan; 89(1):91-6. PubMed ID: 12540958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction.
    Tataru MC; Heinrich J; Junker R; Schulte H; von Eckardstein A; Assmann G; Koehler E
    Eur Heart J; 1999 Oct; 20(20):1493-502. PubMed ID: 10493848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.